ArticleCancer communications (London, England)2018

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.

Qiuyan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.